R1	Has_qualifier Arg1:T2 Arg2:T3	
R2	Has_value Arg1:T4 Arg2:T5	
R3	AND Arg1:T2 Arg2:T4	
*	OR T10 T11 T12
R4	AND Arg1:T9 Arg2:T10	
*	OR T7 T8
R5	AND Arg1:T6 Arg2:T7	
*	OR T6 T9
R6	Has_qualifier Arg1:T15 Arg2:T16	
R7	Has_multiplier Arg1:T15 Arg2:T17	
R8	Has_temporal Arg1:T15 Arg2:T18	
*	OR T19 T20 T21 T22
R9	Has_temporal Arg1:T19 Arg2:T24	
R10	Has_qualifier Arg1:T25 Arg2:T26	
R11	Has_qualifier Arg1:T27 Arg2:T28	
R12	Has_negation Arg1:T31 Arg2:T30	
*	OR T32 T33 T34
R13	Has_negation Arg1:T36 Arg2:T35	
*	OR T37 T38
R14	Has_multiplier Arg1:T40 Arg2:T41	
R15	Has_index Arg1:T48 Arg2:T49	
*	OR T42 T43 T45 T47
R16	Subsumes Arg1:T43 Arg2:T44	
R17	Has_qualifier Arg1:T45 Arg2:T46	
R18	Has_temporal Arg1:T42 Arg2:T48	
R19	Subsumes Arg1:T52 Arg2:T53	
R20	Has_value Arg1:T52 Arg2:T54	
R21	AND Arg1:T51 Arg2:T52	
*	OR T56 T55
R22	Has_qualifier Arg1:T56 Arg2:T57	
R23	AND Arg1:T56 Arg2:T59	
*	OR T60 T61
R24	Has_qualifier Arg1:T62 Arg2:T63	
R25	Has_value Arg1:T62 Arg2:T64	
R26	AND Arg1:T60 Arg2:T62	
R27	Has_qualifier Arg1:T66 Arg2:T67	
R28	Has_negation Arg1:T69 Arg2:T68	
R29	Has_value Arg1:T70 Arg2:T71	
R30	AND Arg1:T79 Arg2:T76	
R31	Has_value Arg1:T79 Arg2:T75	
R32	AND Arg1:T74 Arg2:T78	
R33	Has_value Arg1:T74 Arg2:T77	
*	OR T79 T74
*	OR T72 T73 T79
R34	Has_qualifier Arg1:T81 Arg2:T82	
R35	Subsumes Arg1:T83 Arg2:T84	
R36	Subsumes Arg1:T85 Arg2:T86	
R37	Subsumes Arg1:T87 Arg2:T88	
*	OR T85 T87
R38	Has_value Arg1:T85 Arg2:T89	
R39	Has_value Arg1:T91 Arg2:T92	
*	OR T95 T94
*	OR T97 T96
R40	Has_temporal Arg1:T98 Arg2:T99	
*	OR T103 T105 T104
R41	Has_index Arg1:T106 Arg2:T107	
R42	Has_temporal Arg1:T101 Arg2:T106	
R43	Has_negation Arg1:T103 Arg2:T102	
T1	Condition 0 15	Type 1 diabetes
T2	Condition 30 54	diabetes mellitus type 2
T3	Qualifier 17 29	uncontrolled
T4	Measurement 60 75	fasting glucose
T5	Value 76 89	> 13.3 mmol/l
T6	Condition 136 152	hypersensitivity
T7	Drug 156 169	empagliflozin
T8	Drug 171 182	glimepiride
T9	Condition 231 247	hypersensitivity
T10	Drug 251 264	sulfonylureas
T11	Drug 266 278	sulfonamides
T12	Drug 282 298	SGLT2 inhibitors
T15	Condition 338 359	hypoglycemic episodes
T16	Qualifier 331 337	severe
T17	Multiplier 322 330	multiple
T18	Temporal 371 385	last two years
T19	Drug 394 401	Insulin
T20	Drug 403 418	SGLT2-inhibitor
T21	Drug 420 441	sulfonylurea derivate
T22	Drug 447 454	glinide
T24	Temporal 462 475	past 3 months
T25	Condition 498 511	macular edema
T26	Qualifier 515 524	both eyes
T27	Procedure 544 576	intravitreal anti-VEGF treatment
T28	Qualifier 581 590	both eyes
T29	Non-query-able 623 977	Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included. Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included
T30	Negation 1013 1020	prevent
T31	Procedure 1027 1041	ophthalmoscopy
T32	Condition 1181 1200	vitreous hemorrhage
T33	Condition 1202 1217	mature cataract
T34	Condition 1219 1238	macular pathologies
T35	Negation 1239 1244	other
T36	Condition 1250 1270	diabetic maculopathy
T37	Condition 1283 1295	ketoacidosis
T38	Condition 1299 1317	metabolic acidosis
T39	Drug 1326 1340	loop diuretics
T40	Condition 1357 1377	urogenital infection
T41	Multiplier 1353 1356;1377 1382	> 1 /year
T42	Condition 1399 1405	stroke
T43	Condition 1407 1432	transient ischemic attack
T44	Condition 1434 1437	TIA
T45	Condition 1449 1464	angina pectoris
T46	Qualifier 1440 1448	instable
T47	Condition 1468 1489	myocardial infarction
T48	Temporal 1497 1534	last 3 months prior to baseline visit
T49	Reference_point 1520 1534	baseline visit
T51	Condition 1536 1560	congestive heart failure
T52	Measurement 1561 1587	New York Heart Association
T53	Measurement 1589 1593	NYHA
T54	Value 1595 1605	III and IV
T55	Condition 1626 1662	left ventricular outflow obstruction
T56	Condition 1614 1622;1663 1670	valvular disease
T57	Qualifier 1607 1613	severe
T59	Procedure 1679 1691	intervention
T60	Condition 1694 1713	atrial fibrillation
T61	Condition 1694 1700;1714 1721	atrial flutter
T62	Measurement 1729 1759	mean ventricular response rate
T63	Qualifier 1760 1767	at rest
T64	Value 1768 1789	>100 beats per minute
T66	Condition 1799 1829	lower urinary tract infections
T67	Qualifier 1791 1798	chronic
T68	Negation 1835 1838	not
T69	Condition 1846 1870	asymptomatic bacteriuria
T70	Measurement 1873 1877	eGFR
T71	Value 1878 1897	< 60 ml/min/1,73 m2
T72	Condition 1941 1957	chronic diarrhea
T73	Condition 1981 1997	volume depletion
T74	Measurement 2003 2013	hematocrit
T75	Value 2014 2020	> 48 %
T76	Person 2022 2027	women
T77	Value 2033 2039	> 53 %
T78	Person 2041 2044	men
T79	Measurement 2003 2013	hematocrit
T81	Observation 2056 2082	risk for volume depletion,
T82	Qualifier 2047 2055	elevated
T83	Condition 2154 2175	chronic liver disease
T84	Condition 2193 2209	active hepatitis
T85	Measurement 2228 2248	alanine transaminase
T86	Measurement 2250 2253	ALT
T87	Measurement 2258 2280	aspartate transaminase
T88	Measurement 2282 2285	AST
T89	Value 2287 2314	> 3 x upper limit of normal
T91	Measurement 2388 2416	human immunodeficiency virus
T92	Value 2370 2384	seropositivity
T93	Non-query-able 2419 2516	acute illness at screening or randomization according to judgement by the investigator or patient
T94	Condition 2526 2539	alcohol abuse
T95	Condition 2518 2522;2534 2539	drug abuse
T96	Condition 2558 2578	psychiatric diseases
T97	Condition 2541 2554;2570 2578	psychosomatic diseases
T98	Visit 2589 2604	hospitalization
T99	Temporal 2616 2630	last 12 months
T101	Condition 2661 2671	malignancy
T102	Negation 2677 2686	exception
T103	Condition 2690 2700;2718 2727;2728 2739	basal cell carcinoma of the skin
T104	Condition 2704 2739	squamous cell carcinoma of the skin
T105	Condition 2745 2779	cervical intraepithelial neoplasia
T106	Temporal 2781 2811	5 years prior to randomization
T107	Reference_point 2798 2811	randomization
T109	Non-query-able 2815 2975	ny medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigatorÂ´s judgment
T110	Competing_trial 2977 3101	current participation in any other clinical trial or participation in another clinical trial within 30 days before screening
